



Celldex Therapeutics, Inc.
Investor Relations Department
119 Fourth Avenue
Needham, MA 02494-2725
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: CLDX ¹	
Last Trade:	2.59
Trade Time:	9:38 AM ET Jun 27, 2017
Change:	-0.02 (0.766%)
Day Range	2.59 - 2.64
52-Week Range	2.20 - 5.02
Volume	39,550
Market Cap. (\$M)	324.035
Shares Out (M)	125.110

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 16, 2017*
[Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team](#)
- Jun 16, 2017*
[Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team](#)
- Jun 6, 2017*
[Celldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference](#)
- Jun 6, 2017*
[Celldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference](#)
- Jun 5, 2017*
[Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

- Mar 14, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Definitive Proxy Statement](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2016*
[Quarterly Report \(10-Q\)](#)